YS-ON-001 was granted orphan drug designation by FDA for the treatment of hepatocellular carcinoma. YS-ON-001 is a promising biological product with immunomodulating effects, such as induction of anti-tumor cytokines, activation of NK cells, regulation of macrophage polarization, and suppression of regulatory T cells. YS-ON-001 is a clinical stage biological product based on proprietary immunomodulating cell...
At a time when federal immigration policies are becoming stricter, Kunle Odunsi, director of University of Chicago Medicine Comprehensive Cancer Center, reflected on the fact that cancer research is a highly international community.
